Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Trial Profile

Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Plerixafor (Primary) ; Bevacizumab
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Jan 2017.
    • 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.
    • 15 Jan 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top